Firstly, our data shows that direct targeting of proteins such as CD44[47], CHI3L1[48] or PARD3 may be ineffective at this stage of disease as they are already downregulated in glioma cells at the AOI. This evidence concerns the gene CHI3L1 and central nervous system cancer.